BHVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biohaven Ltd (BHVN) is not a strong buy at the moment for a beginner investor with a long-term horizon. The stock is currently in a bearish technical trend, with weak financial performance and no immediate catalysts to drive significant upside in the near term. While insider buying and analyst optimism regarding its pipeline provide some positive sentiment, the lack of immediate revenue growth, high cash burn, and upcoming pivotal trial results only in the second half of 2026 make this a speculative and high-risk investment. For a beginner investor, it is better to hold off until more concrete positive developments arise.
The technical indicators for BHVN are bearish. The MACD is negatively expanding, RSI is neutral at 30.951, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 9.551 and resistance at 11.728. The recent price drop of -5.26% in the regular market and -2.49% in pre-market further confirms the downward pressure.
Insider buying has increased significantly, up 3226.99% over the last month, indicating confidence from company insiders.
Analysts have raised price targets recently, with TD Cowen increasing its target to $30 and Goldman Sachs to $27, citing optimism around the Kv7 MoA and potential premium pricing for opakalim.
Raymond James maintains a 'Strong Buy' rating, highlighting the opportunity for opakalim in focal epilepsy.
Weak financial performance in Q4 2025, with net income dropping -22.10% YoY and EPS declining -34.59% YoY.
The stock is under bearish technical pressure, with no immediate recovery signals.
The pivotal trial results for opakalim are expected only in the second half of 2026, leaving a long wait for potential catalysts.
The broader market sentiment is negative, with the S&P 500 down -1.52%, which could weigh on the stock.
Biohaven's financial performance in Q4 2025 was weak. Revenue remained at $0, with no YoY growth. Net income dropped to -$145.56M, a decline of -22.10% YoY, and EPS fell to -1.21, down -34.59% YoY. The company is burning cash heavily, which raises concerns about its financial stability in the near term.
Analysts are generally optimistic about Biohaven's long-term potential, with several firms raising price targets recently. TD Cowen raised its target to $30, Goldman Sachs to $27, and Raymond James maintains a 'Strong Buy' rating. However, some analysts, like H.C. Wainwright and BofA, remain cautious due to high cash burn and the long timeline for pivotal trial results. The consensus leans towards a speculative buy for long-term investors willing to take on risk.
